Long-term studies are needed to evaluate the sustained efficacy and safety of SGLT2 inhibitors and GLP-1 RAs, particularly in diverse and underrepresented subpopulations, such as patients with advanced chronic kidney disease or those at high cardiovascular risk with limited comorbidities. The gene discussed is SLC5A2; the disease is chronic kidney disease.